Study
| Randomised, open-label, phase 2 trial |
| Platinum-resistant recurrent or metastatic nasopharyngeal carcinoma |
| Pembrolizumab (200 mg IV q21d) vs. Pembrolizumab (200 mg IV q21d) + Bevacizumab (7.5 mg/kg IV q21d) |
Efficacy
| ORR: 58.3% [36.6–77.9] vs. 12.5% [2.7–32.4] (p=0.0010) |
| mPFS: 13.8 mos [4.2–29.5] vs. 1.6 mos [1.3–2.7] (HR: 0.25 [0.13–0.50]) |
| mOS: 18.5 mos [9.1–NR] vs. 11.7 mos [7.0–16.1] |
Safety
| Grade ≥3 AEs: 29% vs. 8% |
| Common Grade ≥3 AEs: thrombosis or bleeding (17% vs. 0%), colitis (4% vs. 0%), cytopenias (4% vs. 0%), hypertension (4% vs. 0%), proteinuria (4% vs. 0%) |
Lancet Oncol 2025;26:175-86
http://doi.org/10.1016/S1470-2045(24)00677-6
Reviewed by Ulas D. Bayraktar, MD on Mar 2, 2025
